Test Catalog

Test ID: IBDP    
Inflammatory Bowel Disease Serology Panel, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

As an adjunct in the diagnosis of ulcerative colitis and Crohn disease in patients suspected of having inflammatory bowel disease


Not useful to determine the extent of disease in patients with inflammatory bowel disease (IBD) or determine the response to disease-specific therapy including surgical resection of diseased intestine.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Inflammatory bowel disease (IBD) refers to 2 diseases, ulcerative colitis (UC) and Crohn disease (CD), which produce inflammation of the large or small intestines. The diagnosis of these 2 diseases is based on clinical features, the results of barium X-rays, colonoscopy, mucosal biopsy histology, and in some cases operative findings and resected bowel pathology and histology.


Recently, patients with IBD have been shown to have antibodies in serum that help to distinguish between CD and UC.(1) Patients with UC often have measurable neutrophil-specific antibodies (NSA), which react with as yet uncharacterized target antigens in human neutrophils; whereas, patients with CD often have measurable antibodies of the IgA and/or IgG isotypes, which react with cell wall mannan of Saccharomyces cerevisiae strain Su 1.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Saccharomyces cerevisiae ANTIBODY, IgA

Negative: < or =20.0 U

Equivocal: 20.1-24.9 U

Weakly positive: 25.0-34.9 U

Positive: > or =35.0 U


Saccharomyces cerevisiae ANTIBODY, IgG

Negative: < or =20.0 U

Equivocal: 20.1-24.9 U

Weakly positive: 25.0-34.9 U

Positive: > or =35.0 U



Negative (not detectable)

Interpretation Provides information to assist in interpretation of the test results

The finding of neutrophil specific antibodies (NSA) with normal levels of IgA and IgG anti-Saccharomyces cerevisiae antibodies (ASCA) is consistent with the diagnosis of ulcerative colitis (UC); the finding of negative NSA with elevated IgA and IgG ASCA is consistent with Crohn disease (CD).


NSA are detectable in approximately 50% of patients with UC, and elevated levels of either IgA or IgG ASCA occur in approximately 55% of patients with CD. Approximately 40% of patients with CD have elevated levels of both IgA and IgG ASCA.


Employed together, the tests for NSA and ASCA have the following positive predictive values (PV) for UC and CD, respectively: NSA positive with normal levels of IgA and IgG ASCA, PV of 91%; NSA negative with elevated levels if IgA and IgG ASCA, PV of 90%.(2)

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Results from this test should not be exclusively relied upon to establish the diagnosis of ulcerative colitis (UC) or Crohn disease (CD) or to distinguish between these 2 diseases. Some patients with CD have detectable neutrophil specific antibodies (NSA), and some patients with UC have elevated levels of IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA).


Approximately one-third of patients have low titered antinuclear antibodies (ANA), which make it impossible to distinguish the presence or absence of NSA. These results are reported as indeterminate.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Sandborn WJ, Loftus EV Jr, Homburger HA, et al: Evaluation of serological disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001 Aug;7(3):192-201

2. Homburger HA, Unpublished Mayo information

3. Vidrich A, Lee J, Janes E: Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995;Nov15(6):293-299